CN102083824A - 使用cMET和AXL抑制剂和ErbB抑制剂治疗癌症的方法 - Google Patents

使用cMET和AXL抑制剂和ErbB抑制剂治疗癌症的方法 Download PDF

Info

Publication number
CN102083824A
CN102083824A CN2009801261595A CN200980126159A CN102083824A CN 102083824 A CN102083824 A CN 102083824A CN 2009801261595 A CN2009801261595 A CN 2009801261595A CN 200980126159 A CN200980126159 A CN 200980126159A CN 102083824 A CN102083824 A CN 102083824A
Authority
CN
China
Prior art keywords
compound
erbb
cancer
lapatinib
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801261595A
Other languages
English (en)
Chinese (zh)
Inventor
托纳·M·吉尔莫
詹姆斯·G·格雷格
刘莉
石红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41257222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102083824(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN102083824A publication Critical patent/CN102083824A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2009801261595A 2008-05-05 2009-05-05 使用cMET和AXL抑制剂和ErbB抑制剂治疗癌症的方法 Pending CN102083824A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5032208P 2008-05-05 2008-05-05
US61/050,322 2008-05-05
PCT/US2009/042768 WO2009137429A1 (en) 2008-05-05 2009-05-05 Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor

Publications (1)

Publication Number Publication Date
CN102083824A true CN102083824A (zh) 2011-06-01

Family

ID=41257222

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801261595A Pending CN102083824A (zh) 2008-05-05 2009-05-05 使用cMET和AXL抑制剂和ErbB抑制剂治疗癌症的方法

Country Status (19)

Country Link
US (3) US20090274693A1 (enExample)
EP (1) EP2274304A4 (enExample)
JP (1) JP2011519941A (enExample)
KR (1) KR20110004462A (enExample)
CN (1) CN102083824A (enExample)
AR (1) AR071631A1 (enExample)
AU (1) AU2009244453B2 (enExample)
BR (1) BRPI0912582A2 (enExample)
CA (1) CA2723699A1 (enExample)
CL (1) CL2009001063A1 (enExample)
EA (1) EA020779B1 (enExample)
IL (1) IL209057A0 (enExample)
MX (1) MX2010012101A (enExample)
PE (1) PE20091832A1 (enExample)
SG (1) SG190623A1 (enExample)
TW (1) TW201006829A (enExample)
UY (1) UY31800A (enExample)
WO (1) WO2009137429A1 (enExample)
ZA (1) ZA201007722B (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103664879A (zh) * 2012-09-17 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103705521A (zh) * 2012-09-28 2014-04-09 韩冰 一类治疗脑梗塞的化合物及其用途
CN105408312A (zh) * 2013-07-24 2016-03-16 小野药品工业株式会社 喹啉衍生物
CN105939714A (zh) * 2014-02-04 2016-09-14 安斯泰来制药株式会社 以二氨基杂环甲酰胺化合物为有效成分的医药组合物
US10208034B2 (en) 2014-12-25 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
US10836747B2 (en) 2017-01-26 2020-11-17 Ono Pharmaceutical Co., Ltd. Ethane-sulfonate salt of quinoline derivative
CN115073367A (zh) * 2021-03-16 2022-09-20 南京科默生物医药有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833852C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
KR101733773B1 (ko) 2009-01-16 2017-05-10 엑셀리시스, 인코포레이티드 Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
PE20120553A1 (es) 2009-03-25 2012-05-18 Genentech Inc Anticuerpos anti-fgfr3
EP2451445B1 (en) 2009-07-06 2019-04-03 Boehringer Ingelheim International GmbH Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
AR077595A1 (es) * 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
WO2011014872A2 (en) * 2009-07-31 2011-02-03 The Johns Hopkins University Compositions and methods for diagnosing, treating or preventing neoplasias
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
NO2719708T3 (enExample) * 2009-11-13 2018-03-24
SG10201609324UA (en) 2010-07-16 2017-01-27 Exelixis Inc C-met modulator pharmaceutical compositions
PH12013500333A1 (en) 2010-08-20 2013-04-22 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CA2812750C (en) 2010-09-27 2020-10-06 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
WO2012088337A1 (en) * 2010-12-23 2012-06-28 Prometheus Laboratories Inc. Drug selection for malignant cancer therapy using antibody-based arrays
CN102532109B (zh) * 2010-12-27 2015-05-13 浙江海正药业股份有限公司 一种拉帕替尼及其盐的合成方法
CN102093421B (zh) * 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
GEP20247677B (en) 2011-02-10 2024-10-10 Exelixis Inc Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
JP2014513129A (ja) * 2011-05-02 2014-05-29 エクセリクシス， インク． 癌および骨癌疼痛の治療方法
AU2012312364B2 (en) 2011-09-22 2017-11-09 Exelixis, Inc. Method for treating osteoporosis
CN104395284A (zh) 2011-10-20 2015-03-04 埃克塞里艾克西斯公司 制备喹啉衍生物的方法
DK2780338T3 (en) 2011-11-14 2016-12-19 Ignyta Inc Uracil AS AXL- AND C-MET kinase inhibitors
TW201328706A (zh) * 2011-12-05 2013-07-16 Novartis Ag 表皮生長因子受體３（ｈｅｒ３）之抗體
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
NZ627586A (en) 2012-01-31 2016-08-26 Daiichi Sankyo Co Ltd Pyridone derivatives
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
WO2014093750A1 (en) * 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment
KR102276348B1 (ko) 2013-03-15 2021-07-12 엑셀리시스, 인코포레이티드 Ｎ­（４­〔［６,７­비스（메틸옥시）퀴놀린­４­일］옥시〕페닐）­ｎ′­（４­플루오로페닐）시클로프로판­１,１­디카복사미드의 대사물
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
KR102478402B1 (ko) 2013-10-14 2022-12-15 얀센 바이오테크 인코포레이티드 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EA201691850A1 (ru) 2014-03-17 2016-12-30 Экселиксис, Инк. Дозирование составов, содержащих кабозантиниб
US9980966B2 (en) * 2014-04-03 2018-05-29 Merck Patent Gmbh Combinations of cancer therapeutics
KR102223502B1 (ko) 2014-05-09 2021-03-05 삼성전자주식회사 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
MA40386A (fr) 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
EA034992B1 (ru) 2014-08-05 2020-04-15 Экселиксис, Инк. Комбинации лекарственных средств для лечения множественной миеломы
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
RU2748549C2 (ru) 2016-04-15 2021-05-26 Экселиксис, Инк. Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата
WO2017223180A2 (en) 2016-06-21 2017-12-28 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
CN107235896B (zh) * 2016-09-13 2019-11-05 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
CN107235897B (zh) * 2016-09-27 2019-08-16 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
KR102568559B1 (ko) 2016-12-14 2023-08-18 얀센 바이오테크 인코포레이티드 Cd8a-결합 섬유결합소 iii형 도메인
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
CN117137915A (zh) 2017-02-15 2023-12-01 大鹏药品工业株式会社 医药组合物
KR102584306B1 (ko) 2017-09-08 2023-10-04 다이호야쿠힌고교 가부시키가이샤 항종양제 및 항종양 효과 증강제
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN113710322A (zh) * 2019-01-25 2021-11-26 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
US12239710B2 (en) 2021-04-14 2025-03-04 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
US20080058312A1 (en) * 2006-01-11 2008-03-06 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
ITRM20030475A1 (it) * 2003-10-15 2005-04-16 Sipa Societa Industrializzazione P Rogettazione E Impianto e metodo per il condizionamento termico di oggetti
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
EP3168234A1 (en) * 2005-12-15 2017-05-17 Medimmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
AU2007334402B2 (en) * 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors
US8715665B2 (en) * 2007-04-13 2014-05-06 The General Hospital Corporation Methods for treating cancer resistant to ErbB therapeutics
BRPI0721707A2 (pt) * 2007-05-17 2013-01-15 Genentech Inc estruturas de cristal de fragmentos de neuropilina e complexos de neuropilina-anticorpo
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CA2736564A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
US20080058312A1 (en) * 2006-01-11 2008-03-06 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103664879A (zh) * 2012-09-17 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103705521A (zh) * 2012-09-28 2014-04-09 韩冰 一类治疗脑梗塞的化合物及其用途
US10501442B2 (en) 2013-07-24 2019-12-10 Ono Pharmaceuticals Co., Ltd. Quinoline derivative
CN105408312A (zh) * 2013-07-24 2016-03-16 小野药品工业株式会社 喹啉衍生物
US9994549B2 (en) 2013-07-24 2018-06-12 Ono Pharmaceutical Co., Ltd. Quinoline derivative
CN105408312B (zh) * 2013-07-24 2018-09-25 小野药品工业株式会社 喹啉衍生物
US10676462B2 (en) 2013-07-24 2020-06-09 Ono Pharmaceutical Co., Ltd. Quinoline derivative
US10208022B2 (en) 2013-07-24 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
CN105939714A (zh) * 2014-02-04 2016-09-14 安斯泰来制药株式会社 以二氨基杂环甲酰胺化合物为有效成分的医药组合物
US10208034B2 (en) 2014-12-25 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
US10836747B2 (en) 2017-01-26 2020-11-17 Ono Pharmaceutical Co., Ltd. Ethane-sulfonate salt of quinoline derivative
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
CN115073367A (zh) * 2021-03-16 2022-09-20 南京科默生物医药有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途

Also Published As

Publication number Publication date
US20130150363A1 (en) 2013-06-13
SG190623A1 (en) 2013-06-28
TW201006829A (en) 2010-02-16
EA201071268A1 (ru) 2011-06-30
EP2274304A4 (en) 2012-05-30
AU2009244453A1 (en) 2009-11-12
UY31800A (es) 2009-11-10
WO2009137429A1 (en) 2009-11-12
AR071631A1 (es) 2010-06-30
BRPI0912582A2 (pt) 2015-07-28
KR20110004462A (ko) 2011-01-13
EA020779B1 (ru) 2015-01-30
JP2011519941A (ja) 2011-07-14
US20090274693A1 (en) 2009-11-05
CA2723699A1 (en) 2009-11-12
CL2009001063A1 (es) 2010-09-24
AU2009244453B2 (en) 2012-07-19
MX2010012101A (es) 2010-11-30
PE20091832A1 (es) 2009-12-25
EP2274304A1 (en) 2011-01-19
ZA201007722B (en) 2011-08-31
US20130142790A1 (en) 2013-06-06
IL209057A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
AU2009244453B2 (en) Method of treating cancer using a cMET and AXL inhibitor and an erbB inhibitor
EP3903828A1 (en) Combination of antibody-drug conjugate and kinase inhibitor
US10011659B2 (en) Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
KR20100131446A (ko) Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 피리미딘 유도체의 용도
RU2481838C2 (ru) Применение имидазохинолинов для лечения заболеваний, зависимых от egfr, или заболеваний с приобретенной резистентностью к агентам, которые связываются с членами семейства egfr
JP2022027658A (ja) チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物
US20220280499A1 (en) Novel drug combinations for treatment of a carcinoma
US20210260064A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
EP3176183A1 (en) Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
US20230321087A1 (en) Fgfr inhibitor combination therapies
Wang et al. Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
WO2024254298A1 (en) A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
HK40054690A (en) Combination of antibody-drug conjugate and kinase inhibitor
HK40044450A (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110601